CTRI Number |
CTRI/2025/03/082046 [Registered on: 10/03/2025] Trial Registered Prospectively |
Last Modified On: |
|
Post Graduate Thesis |
No |
Type of Trial |
PMS |
Type of Study
|
Other (Specify) [Cosmetics] |
Study Design |
Single Arm Study |
Public Title of Study
|
Eye irritation test of Zydus EqualsTwo Body Wash |
Scientific Title of Study
|
A Clinical Study to Evaluate the Eye Stinging Potential of Zydus EqualsTwo Body Wash on Healthy Human Volunteers |
Trial Acronym |
NIL |
Secondary IDs if Any
|
Secondary ID |
Identifier |
CCFT527 Version 1.0 dated 18 Feb 2025 |
Protocol Number |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Ishika Gandhi |
Designation |
Principal Investigator |
Affiliation |
CCFT Laboratories |
Address |
1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road
Meerut UTTAR PRADESH 250002 India |
Phone |
9868965688 |
Fax |
|
Email |
ishika02gandhi@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Puneet Mittal |
Designation |
Clinical Research Consultant |
Affiliation |
CCFT Laboratories |
Address |
1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road
Meerut UTTAR PRADESH 250002 India |
Phone |
8937015757 |
Fax |
|
Email |
puneetmittal@mgcts.org |
|
Details of Contact Person Public Query
|
Name |
Puneet Mittal |
Designation |
Clinical Research Consultant |
Affiliation |
CCFT Laboratories |
Address |
1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road
UTTAR PRADESH 250002 India |
Phone |
8937015757 |
Fax |
|
Email |
puneetmittal@mgcts.org |
|
Source of Monetary or Material Support
|
CCFT Laboratories, 135, Punjabipura, Delhi Road, Meerut, India 250002 |
Zydus Life Sciences Limited, Plot no-265,266,267 oppostie Laxaminarayan Petrol Pimp, Sarkhej, Amhedabad- 382210 |
|
Primary Sponsor
|
Name |
Zydus Life Sciences Limited |
Address |
Plot no-265,266,267 oppostie Laxaminarayan Petrol Pimp, Sarkhej, Amhedabad- 382210 |
Type of Sponsor |
Pharmaceutical industry-Indian |
|
Details of Secondary Sponsor
|
Name |
Address |
Not Applicable |
Not Applicable |
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Ishika Gandhi |
CCFT laboratories |
First Floor room 1, CCFT laboratories, AR multispecialty hospital and research center, Delhi Road Meerut UTTAR PRADESH |
9027285265
ishika02gandhi@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
ARMHRC Institutional Ethics Committee |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Healthy Human Volunteers |
Not Applicable |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Not Applicable |
Not Applicable |
Intervention |
Test Product: Equals two Body Wash |
Dose: Approx 5 microliter Route: in eyes(on the lower sac) Frequency: Once Duration: 5 mins |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
60.00 Year(s) |
Gender |
Both |
Details |
1.Healthy males or females, 18 to 60 years with no medical conditions of the eyes as determined by the subjects medical history and confirmed by an ophthalmologist
2. Subjects not under any doctor care for ocular or peri orbital diseases
3. The subject will refrain from using contact lenses, any topical facial products, any eye drops, false eyelashes, make up, over the counter products, or cosmetics on their eyes, eyelids, eyelashes, or the periorbital areas of the face during the study. |
|
ExclusionCriteria |
Details |
1.Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study.
2.Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition.
3.Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product.
4.Have participated in any interventional clinical trial in the previous 30 days.
5.Have a known sensitivity to any of the constituents of the test product including sensitivities to cocoamidopropyl betaine, coumarin, Aloe barbadensis etc.
6.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids.
7.Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years. |
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Open Label |
Primary Outcome
|
Outcome |
TimePoints |
Change in lacrimation
|
0min, 1min, 5min |
|
Secondary Outcome
|
Outcome |
TimePoints |
Change in conjunctival inflammation |
0min, 1min, 5min |
Change in cornea and iris inflammation |
0min, 1min, 5min |
Change in Subject Discomfort |
0min, 1min, 5min |
|
Target Sample Size
|
Total Sample Size="32" Sample Size from India="32"
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="0" |
Phase of Trial
|
Post Marketing Surveillance |
Date of First Enrollment (India)
|
19/03/2025 |
Date of Study Completion (India) |
Date Missing |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Date Missing |
Estimated Duration of Trial
|
Years="0" Months="0" Days="2" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Completed |
Publication Details
|
N/A |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
single arm clinical study. 5 μL of the appropriate test should be instilled into the lower conjunctival sac of one eye, and another eye should be instilled with Normal Saline as Negative control. No Positive control to be taken. Assessment would be done as 5-point scale for the below attributes after 1 min/2 min/5 min. 1. Subjective discomfort, Score 0: No discomfort felt Score 1: Faint, barely perceptible discomfort Score 2: Mild, low intensity discomfort that does not prevent the subject from opening lids Score 3: Moderately intense discomfort that interferes with but does not prevent lid opening Score 4: Severe, very intense discomfort that makes voluntary lid opening difficult, requires force to pull lids apart, and results in the subject requesting washout of test article 2. Objective lacrimation, Score 0: No tearing or lid wetness above normal Score 1: Noticeable increase in moistness of lid edges - no frank tearing Score 2: Frank tearing - meager flow Score 3: Frank tearing - moderate flow Score 4: Frank tearing - copious flow 3. Objective conjunctival inflammation, Score 0: Inflammatory changes absent Score 1: Capillaries slightly more prominent than they were at time of baseline examination Score 2: Capillaries very prominent plus some diffuse conjunctival reddening Score 3: Vessels very prominent plus diffuse and confluent intense redness Score 4: Beefy redness and everted lids 4. Objective cornea and iris inflammation Score 0: No effect detected with use of slit lamp Score 1: Barely perceptible clouding or pitting of cornea or thickening of iris detected via slit lamp Score 2: Faint clouding or pitting of cornea and/or thickening of the iris Score 3: Moderate clouding or pitting of cornea and/or thickening of the iris Score 4: Intense clouding orpitting of cornea and/or thickening of the iris A follow-up visit is done after 24 hours to assess any adverse effect after the Product application |